Our Pricing

Understanding the Monthly Cost for Weight Loss Injections in Scotland

The monthly cost for weight loss injections in Scotland varies significantly depending on which medication your prescriber recommends, with options ranging from daily injections to once-weekly pens. At Cured Pharmacy, Scottish patients access transparent upfront pricing on all licensed weight loss treatments including Mounjaro from £135.00, with free online consultation from UK-registered prescribers and discreet delivery across Scotland.

Monthly Cost for Weight Loss Injections in Scotland: What to Expect

Scottish patients considering prescription weight loss injections typically face monthly costs determined by three factors: the active ingredient, dosing frequency, and prescribed strength. Injectable GLP-1 receptor agonists—the gold standard for medical weight management—work by mimicking natural gut hormones that regulate appetite and blood sugar, with clinical trials demonstrating average weight reductions of 15-22.5% over 12-18 months [1][2].

At Cured Pharmacy, monthly costs reflect the actual medication required. Mounjaro (tirzepatide) starts from £135.00 per month depending on your prescribed dose, whilst alternatives like Saxenda require daily injections with different cost structures. All prescription weight loss treatments dispensed to Scottish patients require clinical assessment by a UK-registered prescriber, ensuring the chosen medication suits your medical history and weight management goals.

Understanding these costs upfront helps Scottish patients make informed decisions. Unlike some providers who reveal pricing only after lengthy consultations, Cured Pharmacy displays transparent pricing before you begin your free three-minute online assessment, with no hidden consultation fees or subscription charges.

How Mounjaro and Tirzepatide Work for Weight Management

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Unlike single-pathway medications, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced metabolic effects that extend beyond appetite suppression alone.

In the landmark SURMOUNT-1 trial, participants receiving the highest maintenance dose of tirzepatide achieved an average 22.5% reduction in body weight over 72 weeks—significantly greater than any previous obesity medication studied in head-to-head comparisons [1]. The dual-receptor mechanism appears to enhance insulin sensitivity, reduce hepatic glucose production, and slow gastric emptying more effectively than single-agonist treatments.

Scottish patients prescribed Mounjaro begin with a lower starter dose, gradually titrating upward over 16-20 weeks to minimise gastrointestinal side effects whilst the body adapts. This dose-escalation protocol, standard across UK prescribing guidelines, allows most patients to reach therapeutic doses with manageable tolerability. Your UK prescriber determines the optimal maintenance dose based on your weight loss response and any side effects experienced during titration.

Tirzepatide Clinical Evidence

The SURMOUNT clinical trial programme enrolled over 5,000 participants across multiple studies, establishing tirzepatide's efficacy profile in real-world populations including those with and without type 2 diabetes [1]. Scottish patients prescribed Mounjaro can expect gradual, sustained weight reduction when combined with lifestyle modifications including reduced calorie intake and increased physical activity—both essential components of any medical weight management programme.

Importantly, clinical trials demonstrated that weight loss with tirzepatide was accompanied by improvements in cardiometabolic markers including blood pressure, lipid profiles, and inflammatory markers [1]. These secondary benefits may reduce long-term cardiovascular risk in patients with obesity, though tirzepatide is not licensed specifically for cardiovascular protection in the UK.

Comparing Monthly Costs: Mounjaro vs Wegovy vs Saxenda

Scottish patients often ask how different weight loss injections compare in terms of monthly cost and clinical efficacy. Whilst all three licensed options—Mounjaro, Wegovy, and Saxenda—belong to the GLP-1 receptor agonist class, they differ in dosing frequency, mechanism of action, and published weight loss outcomes.

Wegovy contains semaglutide, a once-weekly GLP-1 receptor agonist that demonstrated average weight reductions of 14.9% over 68 weeks in the STEP-1 trial [2]. Saxenda contains liraglutide, an earlier-generation daily injection that produces more modest weight loss averaging 8% in clinical trials [3]. Mounjaro's dual-receptor mechanism has shown superior efficacy in head-to-head studies, though individual response varies and some patients achieve excellent results with any of these medications.

Cost considerations extend beyond the medication price alone. Once-weekly injections like Mounjaro and Wegovy offer convenience that may improve long-term adherence compared to daily Saxenda injections. However, daily dosing allows more flexible titration for patients who experience side effects, and some prescribers prefer starting with Saxenda before escalating to more potent options if needed.

Which Injection Suits Scottish Patients Best?

Your UK prescriber will recommend a specific weight loss injection based on your medical history, current medications, previous weight loss attempts, and personal preferences regarding injection frequency. Patients with type 2 diabetes may benefit particularly from Mounjaro's dual mechanism, whilst those seeking lower initial costs might start with alternative options and escalate if needed.

All three medications require subcutaneous injection—typically into the abdomen, thigh, or upper arm—using pre-filled pens designed for home use. Scottish patients receive full injection training materials with their first prescription, and our clinical team remains available for ongoing support throughout your weight management journey.

Additional Weight Loss Treatment Options Available in Scotland

Whilst GLP-1 receptor agonist injections represent the most effective pharmacological option for weight management, Scottish patients may also consider oral medications depending on their clinical situation and preferences. Orlistat—available as prescription-strength Xenical or lower-dose Orlos and Alli—works through a completely different mechanism by blocking approximately 30% of dietary fat absorption in the intestine [4].

Orlistat suits patients who prefer tablets over injections, though clinical trials show more modest weight loss averaging 3-5% compared to injectable GLP-1 treatments [4]. The medication requires adherence to a reduced-fat diet to minimise gastrointestinal side effects, and it may not be suitable for patients with certain digestive conditions. However, for Scottish patients seeking a non-injectable option or those with contraindications to GLP-1 medications, orlistat provides a licensed alternative.

Cured Pharmacy also offers pre-orders for Wegovy oral tablets (semaglutide pill), recently licensed in the UK as the first oral GLP-1 medication for weight management. This option combines the efficacy of semaglutide with the convenience of a daily tablet, though it requires specific administration instructions including taking on an empty stomach with minimal water.

What's Included in Your Monthly Cost at Cured Pharmacy

The monthly cost for weight loss injections in Scotland through Cured Pharmacy includes several services beyond the medication itself. Every prescription begins with a free online consultation completed in under three minutes, reviewed by UK-registered prescribers who assess your eligibility based on current MHRA and NICE guidelines for obesity medications.

Once approved, your medication is dispensed from our GPhC-registered pharmacy (registration number 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). All medications are genuine UK-licensed products—never grey imports or unlicensed compounds—shipped in 100% discreet packaging with no external branding. Scottish patients typically receive delivery within 2-3 working days via Royal Mail or courier service.

Ongoing prescribing support is included at no additional charge. As you progress through dose titration or if you experience side effects requiring dose adjustment, simply contact our clinical team for guidance. Follow-up consultations for repeat prescriptions are free, ensuring your monthly cost remains predictable without hidden consultation fees that some providers charge for routine prescription renewals.

Transparent Pricing for Scottish Patients

Cured Pharmacy displays all medication pricing upfront before you begin your consultation, allowing Scottish patients to make informed decisions about which treatment fits their budget. Our lowest price guarantee ensures you're getting competitive UK pricing without sacrificing quality or clinical oversight. If you find a lower price from another UK-registered pharmacy for the same licensed medication, we'll match it.

Monthly costs may vary as you titrate to higher maintenance doses—for example, Mounjaro patients typically start at lower doses before escalating to the most effective strength over several months. Your prescriber will discuss expected long-term costs during your initial consultation, ensuring no surprises as your treatment progresses.

Starting Your Weight Loss Journey: Next Steps for Scottish Patients

Beginning prescription weight loss treatment in Scotland through Cured Pharmacy starts with a brief online consultation accessible from any device. The assessment asks about your current weight, height, medical history, existing medications, and previous weight loss attempts—information your prescriber needs to determine which treatment suits you best and whether any contraindications exist.

If approved, your prescriber will issue a prescription for the most appropriate medication and starting dose. Scottish patients with certain medical conditions including previous pancreatitis, active gallbladder disease, or personal/family history of medullary thyroid carcinoma may not be suitable candidates for GLP-1 medications, in which case alternative options like orlistat may be recommended instead.

Weight loss injections work most effectively when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity. Your prescriber will provide guidance on realistic weight loss expectations—typically 0.5-1kg per week during active treatment—and recommend follow-up intervals to monitor your progress. Most Scottish patients remain on treatment for 12-18 months to achieve and consolidate their weight loss goals before considering medication discontinuation under medical supervision.

Monitoring and Long-Term Success

Successful weight management extends beyond reaching your target weight. Clinical evidence suggests that many patients regain weight after stopping GLP-1 medications, which is why prescribers often recommend extended treatment durations followed by gradual dose reduction rather than abrupt cessation [2]. Your UK prescriber will discuss maintenance strategies as you approach your goals, potentially including lower maintenance doses or transitioning to lifestyle-only management with close monitoring.

Scottish patients should schedule regular check-ins with their prescriber every 3-6 months during active treatment to assess efficacy, tolerability, and any necessary dose adjustments. Cured Pharmacy's clinical team remains available between scheduled reviews if you experience concerning side effects or have questions about your treatment progress.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss medications work most effectively when combined with reduced calorie intake and increased physical activity.